Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Stock Short Interest Declines 95.6%

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 19,900 shares, a decrease of 95.6% from the September 15th total of 451,633 shares. Approximately 7.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,643,901 shares, the short-interest ratio is presently 0.0 days.

Scinai Immunotherapeutics Trading Down 2.5%

NASDAQ SCNI traded down $0.03 on Friday, hitting $1.18. The company’s stock had a trading volume of 19,238 shares, compared to its average volume of 3,088,570. The firm has a market cap of $834,260.00, a P/E ratio of -0.01 and a beta of 2.13. Scinai Immunotherapeutics has a 52-week low of $1.06 and a 52-week high of $15.65. The company’s 50-day simple moving average is $2.06 and its 200 day simple moving average is $3.55. The company has a current ratio of 1.56, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Scinai Immunotherapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, October 6th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company’s research centers on NanoAb, its proprietary platform of single-domain antibodies designed to target disease-related proteins and potentially support localized treatment with reduced systemic exposure.

Scinai’s lead development program is SCNI-153, a NanoAb-based candidate targeting interleukin-17 (IL-17) for the treatment of plaque psoriasis.